Loading...
 
Mediterr J Rheumatol 2021;32(4):367-8
Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy
Authors Information

1. Department of Physiology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

2. Molecular Oncology Unit, Department of Biological Chemistry, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

3. Evgenidio Treatment Center, “Agia Trias”, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

References
  1. Simonsen AB, Kaae J, Ellebaek E, Svane IM, Zachariae C. Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review. J Am Acad Dermatol 2020 Nov;83(5):1415-24.
  2. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 2015;151:1206-12.
  3. Aso M, Toi Y, Sugisaka J, Aiba T, Kawana S, Saito R, et al. Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. Oncologist 2020;25:e536-44.
  4. Peled M, Strazza M, Azoulay-Alfaguter I, Silverman GJ, Scher JU, Mor A. Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis. Inflammation 2015;38:1573-9.